R&D channel feed – Endpoints News

R&D channel feed

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

4 months ago

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

4 months ago

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

4 months ago

‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies

4 months ago

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

4 months ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

4 months ago

With schizophrenia trial success, LB Pharmaceuticals thinks about Phase 3 and next funding

4 months ago

Jasper reports more data in spontaneous hives from tiny study

4 months ago

Calico, Denali's ALS drugs miss primary objectives in basket study

4 months ago

Immuneering touts positive pancreatic cancer data for MEK inhibitor

4 months ago

Metsera’s long-acting GLP-1 looks competitive in Phase 2 obesity study

4 months ago

Profluent debuts AI model for CRISPR design, hoping to expand gene editing's potential

4 months ago

Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia as it looks beyond Casgevy

4 months ago

Ken Song's Candid licenses a T cell engager from WuXi Bio

4 months ago

Exclusive: Highlander Health, co-founded by ex-Verily execs, makes first acquisition

4 months ago

Updated: Acelyrin’s stock drops due to mixed Phase 2 data in thyroid eye disease

4 months ago

Oculis’ eye drug clears Phase 2 in France as US development beckons

4 months ago

GSK’s Nucala bags another China approval, but biggest test yet to come

4 months ago

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

4 months ago

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

4 months ago

Neumora's major depression drug flunks first of three Phase 3 trials

4 months ago

Roche circles back to China biotech with $80M deal for lung cancer ADC

4 months ago

Flagship biotech Valo Health ends 2024 with mid-stage fail

4 months ago

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

4 months ago

First page Previous page 10 11 121314 15 16 Next page Last page